Clinical Observation of Paclitaxel Combined with Lobaplatin by Interventional Embolization Chemothera-py for Cervical Cancer / 中国药房

ABSTRACT

OBJECTIVE:To investigate chemotherapeutic efficacy and safety of Paclitaxel combined with lobaplatin by inter-ventional embolization for cervical cancer. METHODS:Totally 68 cases of cervical cancer patients selected from our hospital dur-ing May 2010-Mar. 2014 were divided into control group and observation group according to therapy plan,with 34 cases in each group. Control group was given Paclitaxel liposome for injection 175 mg/m2 added into 5% Glucose injection 250 mL,ivgtt+Loba-platin for injection 80 mg/m2 added into 5% Glucose injection 250 mL,ivgtt. Observation group was given Paclitaxel liposome for injection 175 mg/m2+Lobaplatin for injection 80 mg/m2+5% Glucose injection 10 mL via percutaneous catheter after selecting uter-ine artery and tumor vessel by arterial catheterization arteriography,gelfoam embolization. Both groups were treated in the first day of every treatment course,21 d as a treatment course,for 3 courses. Clinical efficacies were observed in 2 groups as well as the levels of T lymphocyte subsets(CD4+,CD8+,CD4+/CD8+)before and after treatment. The occurrence of ADR during treatment,lo-cal recurrence and metastasis after 2 years,and survival situation were recorded. RESULTS:The total response rate of observatio group(85.29%)was significantly higher than that of control group(61.76%),with statistical significance(P0.05). After treat-ment,CD4+and CD4+/CD8+of 2 groups were increased significantly,while CD8+was decreased significantly;above indexes of ob-servation group were improved significantly compared to control group,with statistical significance (P0.05). CONCLUSIONS:Paclitaxel combined with lobaplatin by interventional embolization show definite chemotherapeutic efficacy for cervical cancer,and can improve the levels of T lymphocyte subset with good safety.